U.K. – Revvity, Inc. has deepened its partnership with Genomics England to accelerate genomic research and initiatives across the United Kingdom.
This enhanced collaboration focuses on advancing critical areas of genomics, with a particular emphasis on the Generation Study, which aims to improve early detection and intervention for rare genetic conditions in newborns.
A central element of the partnership is the Generation Study, a groundbreaking project conducted in collaboration with the National Health Service (NHS).
The study seeks to screen up to 100,000 newborns in England for 200 rare genetic conditions. Utilizing Revvity’s chemagic 360 instrument, researchers will extract DNA from cord blood samples to identify conditions early, enabling prompt diagnosis and treatment.
“This partnership is an important contributor to our goal of researching earlier diagnosis and intervention for rare genetic conditions in newborns,” said Ellen Thomas, PhD, MD, Chief Medical Officer at Genomics England.
“By uniting Genomics England’s research expertise with Revvity’s advanced laboratory capabilities, we are proud to reinforce our commitment to advancing genomics research.”
Revvity’s Omics laboratory in Manchester will play a pivotal role in the study, marking the city as a growing hub for molecular genomics and innovation.
The location reflects a deliberate effort to expand the UK’s talent pool in cutting-edge genomic research.
Commitment to genomic innovation
Revvity has been a long-standing collaborator with Genomics England, and this expanded partnership underscores both organizations’ dedication to advancing genomic research and improving healthcare outcomes.
“We’re grateful for the opportunity to expand our relationship with Genomics England to make a greater impact in saving the lives of babies with this new project,” said Madhuri Hegde, PhD, FACMG, Revvity’s Senior Vice President and Chief Scientific Officer.
Revvity Transcribe AI
In addition to its work on the Generation Study, Revvity recently unveiled Revvity Transcribe AI, an artificial intelligence-powered optical character recognition (OCR) solution designed to streamline workflows in clinical laboratories.
The tool digitizes handwritten test request forms, reducing errors and improving data entry speed by 40%.
While beneficial for a range of applications, this service is especially valuable for newborn screening (NBS) laboratories and is compatible with the EVOYA platform, Revvity’s NBS software solution.
Public screening labs process hundreds of handwritten dried blood spot (DBS) test cards every day, and by deploying Revvity Transcribe AI, the manual data entry resource can instead be made available for other tasks within the laboratory.
By automating data transcription, laboratory personnel can focus on other critical tasks.
“With the new Revvity Transcribe AI solution, labs can swiftly transcribe handwritten information on test request forms using advanced AI-supported OCR technology,” said Norm Lord, Vice President of Digital Products at Revvity.
“This service ensures that digitized data is securely processed and seamlessly integrated into laboratory information management systems for review and verification.”
The Revvity Transcribe AI solution was showcased at the 2024 APHL Newborn Screening Symposium, where it received attention for its potential to revolutionize data management in laboratory workflows.
